{"id":1007219,"date":"2026-09-30T16:04:10","date_gmt":"2026-09-30T20:04:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-results-of-mrt-8102-gforce-1-phase-1-study-in-subjects-with-elevated-cardiovascular-disease-risk\/"},"modified":"2026-09-30T16:04:10","modified_gmt":"2026-09-30T20:04:10","slug":"monte-rosa-therapeutics-to-present-results-of-mrt-8102-gforce-1-phase-1-study-in-subjects-with-elevated-cardiovascular-disease-risk","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-results-of-mrt-8102-gforce-1-phase-1-study-in-subjects-with-elevated-cardiovascular-disease-risk\/","title":{"rendered":"Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk"},"content":{"rendered":"

\nConference call and webcast to be held at 8:00 a.m. ET on Oct. 1, 2026
\n<\/h2>\n
\n

BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc.<\/u><\/a> (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will host a live conference call and webcast on\u00a0Thursday, October 1, at\u00a08:00 a.m. ET. The webcast presentation will review clinical results from the GFORCE-1 Phase 1 study of the NEK7-directed MGD MRT-8102 in subjects with elevated cardiovascular disease (CVD) risk. The presentation will include safety and activity data for MRT-8102 across multiple dose levels following 4 weeks of treatment and will showcase pioneering data on the modulation of multiple pathogenic drivers of atherosclerotic cardiovascular disease (ASCVD) by MRT-8102.<\/p>\n

A webcast of the presentation will be accessible via the \u201cEvents & Presentations\u201d section of Monte Rosa\u2019s website at\u00a0ir.monterosatx.com<\/a>. Registration for the conference call is available at the following\u00a0link<\/a>. An archived version of the webcast will be made available for 30 days following the presentation.<\/p>\n

\n About Monte Rosa<\/strong>
\n
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa\u2019s QuEEN\u2122 (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry\u2019s leading pipeline of first-in-class and only-in-class MGDs, spanning autoimmune and inflammatory diseases, oncology, and beyond, with three programs in the clinic. Monte Rosa has ongoing collaborations with leading pharmaceutical companies in the areas of immunology, oncology, and neurology. For more information, visit www.monterosatx.com<\/a>.<\/p>\n

\n Investors<\/strong>
\n
Andrew Funderburk
ir@monterosatx.com<\/u><\/a><\/p>\n

\n Media<\/strong>
\n
Cory Tromblee, Scient PR
media@monterosatx.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Conference call and webcast to be held at 8:00 a.m. ET on Oct. 1, 2026 BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will host a live conference call and webcast on\u00a0Thursday, October 1, at\u00a08:00 a.m. ET. The webcast presentation will review clinical results from the GFORCE-1 Phase 1 study of the NEK7-directed MGD MRT-8102 in subjects with elevated cardiovascular disease (CVD) risk. The presentation will include safety and activity data for MRT-8102 across multiple dose levels following 4 weeks of treatment and will showcase pioneering data on the modulation of multiple pathogenic drivers of atherosclerotic cardiovascular disease (ASCVD) by … <\/p>\n

Continue reading “Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1007219","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMonte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-results-of-mrt-8102-gforce-1-phase-1-study-in-subjects-with-elevated-cardiovascular-disease-risk\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Conference call and webcast to be held at 8:00 a.m. ET on Oct. 1, 2026 BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will host a live conference call and webcast on\u00a0Thursday, October 1, at\u00a08:00 a.m. ET. The webcast presentation will review clinical results from the GFORCE-1 Phase 1 study of the NEK7-directed MGD MRT-8102 in subjects with elevated cardiovascular disease (CVD) risk. The presentation will include safety and activity data for MRT-8102 across multiple dose levels following 4 weeks of treatment and will showcase pioneering data on the modulation of multiple pathogenic drivers of atherosclerotic cardiovascular disease (ASCVD) by … Continue reading "Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-results-of-mrt-8102-gforce-1-phase-1-study-in-subjects-with-elevated-cardiovascular-disease-risk\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-30T20:04:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNzIyMyM3ODcyNzEzIzIyMDk1NDU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-results-of-mrt-8102-gforce-1-phase-1-study-in-subjects-with-elevated-cardiovascular-disease-risk\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-results-of-mrt-8102-gforce-1-phase-1-study-in-subjects-with-elevated-cardiovascular-disease-risk\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk\",\"datePublished\":\"2026-09-30T20:04:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-results-of-mrt-8102-gforce-1-phase-1-study-in-subjects-with-elevated-cardiovascular-disease-risk\\\/\"},\"wordCount\":326,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-results-of-mrt-8102-gforce-1-phase-1-study-in-subjects-with-elevated-cardiovascular-disease-risk\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNzIyMyM3ODcyNzEzIzIyMDk1NDU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-results-of-mrt-8102-gforce-1-phase-1-study-in-subjects-with-elevated-cardiovascular-disease-risk\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-results-of-mrt-8102-gforce-1-phase-1-study-in-subjects-with-elevated-cardiovascular-disease-risk\\\/\",\"name\":\"Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-results-of-mrt-8102-gforce-1-phase-1-study-in-subjects-with-elevated-cardiovascular-disease-risk\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-results-of-mrt-8102-gforce-1-phase-1-study-in-subjects-with-elevated-cardiovascular-disease-risk\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNzIyMyM3ODcyNzEzIzIyMDk1NDU=\",\"datePublished\":\"2026-09-30T20:04:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-results-of-mrt-8102-gforce-1-phase-1-study-in-subjects-with-elevated-cardiovascular-disease-risk\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-results-of-mrt-8102-gforce-1-phase-1-study-in-subjects-with-elevated-cardiovascular-disease-risk\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-results-of-mrt-8102-gforce-1-phase-1-study-in-subjects-with-elevated-cardiovascular-disease-risk\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNzIyMyM3ODcyNzEzIzIyMDk1NDU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNzIyMyM3ODcyNzEzIzIyMDk1NDU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-results-of-mrt-8102-gforce-1-phase-1-study-in-subjects-with-elevated-cardiovascular-disease-risk\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-results-of-mrt-8102-gforce-1-phase-1-study-in-subjects-with-elevated-cardiovascular-disease-risk\/","og_locale":"en_US","og_type":"article","og_title":"Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk - Market Newsdesk","og_description":"Conference call and webcast to be held at 8:00 a.m. ET on Oct. 1, 2026 BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will host a live conference call and webcast on\u00a0Thursday, October 1, at\u00a08:00 a.m. ET. The webcast presentation will review clinical results from the GFORCE-1 Phase 1 study of the NEK7-directed MGD MRT-8102 in subjects with elevated cardiovascular disease (CVD) risk. The presentation will include safety and activity data for MRT-8102 across multiple dose levels following 4 weeks of treatment and will showcase pioneering data on the modulation of multiple pathogenic drivers of atherosclerotic cardiovascular disease (ASCVD) by … Continue reading \"Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-results-of-mrt-8102-gforce-1-phase-1-study-in-subjects-with-elevated-cardiovascular-disease-risk\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-30T20:04:10+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNzIyMyM3ODcyNzEzIzIyMDk1NDU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-results-of-mrt-8102-gforce-1-phase-1-study-in-subjects-with-elevated-cardiovascular-disease-risk\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-results-of-mrt-8102-gforce-1-phase-1-study-in-subjects-with-elevated-cardiovascular-disease-risk\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk","datePublished":"2026-09-30T20:04:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-results-of-mrt-8102-gforce-1-phase-1-study-in-subjects-with-elevated-cardiovascular-disease-risk\/"},"wordCount":326,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-results-of-mrt-8102-gforce-1-phase-1-study-in-subjects-with-elevated-cardiovascular-disease-risk\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNzIyMyM3ODcyNzEzIzIyMDk1NDU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-results-of-mrt-8102-gforce-1-phase-1-study-in-subjects-with-elevated-cardiovascular-disease-risk\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-results-of-mrt-8102-gforce-1-phase-1-study-in-subjects-with-elevated-cardiovascular-disease-risk\/","name":"Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-results-of-mrt-8102-gforce-1-phase-1-study-in-subjects-with-elevated-cardiovascular-disease-risk\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-results-of-mrt-8102-gforce-1-phase-1-study-in-subjects-with-elevated-cardiovascular-disease-risk\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNzIyMyM3ODcyNzEzIzIyMDk1NDU=","datePublished":"2026-09-30T20:04:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-results-of-mrt-8102-gforce-1-phase-1-study-in-subjects-with-elevated-cardiovascular-disease-risk\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-results-of-mrt-8102-gforce-1-phase-1-study-in-subjects-with-elevated-cardiovascular-disease-risk\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-results-of-mrt-8102-gforce-1-phase-1-study-in-subjects-with-elevated-cardiovascular-disease-risk\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNzIyMyM3ODcyNzEzIzIyMDk1NDU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNzIyMyM3ODcyNzEzIzIyMDk1NDU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-results-of-mrt-8102-gforce-1-phase-1-study-in-subjects-with-elevated-cardiovascular-disease-risk\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1007219","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1007219"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1007219\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1007219"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1007219"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1007219"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}